Chronic Hepatitis C Infection Clinical Trial
— MALACHITE 1Official title:
A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)
Verified date | July 2016 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.
Status | Completed |
Enrollment | 311 |
Est. completion date | July 2015 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Males or females between 18 and 65 years, inclusive, at time of Screening - Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control - Subject has never received antiviral treatment for hepatitis C infection - Chronic HCV Genotype-1 infection prior to study enrollment Exclusion Criteria: - Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) - Females who are pregnant or plan to become pregnant, or breastfeeding - Any current or past clinical evidence of cirrhosis - Screening laboratory analyses that showing abnormal laboratory results - Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV - Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol - Positive screen for drugs or alcohol |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
Dore GJ, Conway B, Luo Y, Janczewska E, Knysz B, Liu Y, Streinu-Cercel A, Caruntu FA, Curescu M, Skoien R, Ghesquiere W, Mazur W, Soza A, Fuster F, Greenbloom S, Motoc A, Arama V, Shaw D, Tornai I, Sasadeusz J, Dalgard O, Sullivan D, Liu X, Kapoor M, Camp — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses | The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. | 12 weeks after the last actual dose of active study drug | |
Secondary | Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS) | SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL). | From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E | |
Secondary | Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS) | SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL). | From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E | |
Secondary | Percentage of Participants With SVR12 - Secondary Efficacy Analyses | The percentage of participants with sustained virologic response (plasma HCV RNA level < LLOQ) 12 weeks after the last dose of study drug. | 12 weeks after the last actual dose of active study drug | |
Secondary | Percentage of Participants With Virologic Failure During Treatment | Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy: Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of >1 log10 IU/mL above nadir) at any time point during treatment Failure to achieve HCV RNA < LLOQ by Week 6 or Confirmed HCV RNA = LLOQ (defined as 2 consecutive HCV RNA measurements = LLOQ) at any point after HCV RNA < LLOQ during treatment after HCV RNA < LLOQ. Participants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows: HCV RNA > 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV HCV RNA > 1000 IU/mL at Week 12, discontinue pegIFN and RBV Confirmed HCV RNA > lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV Confirmed HCV RNA > LLOD at Week 36, discontinue pegIFN and RBV. |
12 weeks for Arms A, C and D and 24 weeks or 48 weeks for Arms B and E | |
Secondary | Percentage of Participants With Post-treatment Relapse | Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment. | Within 24 weeks post treatment | |
Secondary | Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24) | The percentage of participants with sustained virologic response (plasma HCV RNA level < LLOQ) 24 weeks after the last dose of study drug. | 24 weeks after the last actual dose of active study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02216422 -
A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection
|
Phase 3 | |
Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
Completed |
NCT01700179 -
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
|
Phase 1 | |
Completed |
NCT02486406 -
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT01704755 -
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT01225380 -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
|
Phase 2 | |
Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
Completed |
NCT02065999 -
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
|
||
Completed |
NCT01716585 -
A Study to Evaluate Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT01715415 -
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
|
Phase 3 | |
Completed |
NCT01453075 -
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
|
Phase 1 | |
Completed |
NCT01011166 -
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
|
Phase 2 | |
Completed |
NCT00557583 -
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
|
Phase 1 | |
Terminated |
NCT01586325 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
|
Phase 1 | |
Recruiting |
NCT02583685 -
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
|
Phase 2 | |
Recruiting |
NCT02578693 -
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
|
||
Completed |
NCT02576314 -
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
|
Phase 3 | |
Not yet recruiting |
NCT01835938 -
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
|
Phase 1/Phase 2 | |
Completed |
NCT01055821 -
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
|
Phase 2 | |
Completed |
NCT01833533 -
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
|
Phase 3 |